Regulations.gov document
2022-001051 - Welle North America Inc. - 1 - WelleCo The Clarity Elixir - Supports mental…
Other · FDA-2022-S-0024 · posted Nov 25, 2022
Key facts
| Document ID | FDA-2022-S-0024-1012 |
|---|---|
| Title | 2022-001051 - Welle North America Inc. - 1 - WelleCo The Clarity Elixir - Supports mental concentration, focus and clarity |
| Document type | Other |
| Subtype | 30 Day Structured Function Claim |
| Agency | FDA |
| Docket | FDA-2022-S-0024 |
| Posted | Nov 25, 2022 |
| Comment period opens | Nov 25, 2022 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: